现代血糖监测与胰岛素输注技术对1型糖尿病患者报告结局与体验的影响:系统综述与荟萃分析
该系统综述与荟萃分析检索2013年至2025年8月多个数据库,纳入81项纵向研究共19148名非妊娠成人1型糖尿病患者,评估糖尿病技术对患者报告结局指标(PROMs)的影响。结果显示,技术使用与低血糖恐惧评分降低相关,对治疗满意度有中等正向效应,对糖尿病痛苦和问题区域评分有轻至中度降低。
要点
- 糖尿病技术可降低成人1型糖尿病患者的低血糖恐惧,自动胰岛素输注装置使用者效应最大。
- 技术使用对治疗满意度有中等正向效应,对糖尿病痛苦和PAID评分有轻至中度降低。
- 报告的PROMs种类繁多(70种),提示需标准化PROMs的使用。
核心结论
- 糖尿病技术为成人1型糖尿病患者带来心理获益。
- 大量使用的PROMs提示需要标准化其应用。
研究设计与样本
- 系统综述与随机效应荟萃分析,检索Cochrane Library CENTRAL、Embase、MEDLINE、Scopus和Web of Science从2013年至2025年8月的文献。
- 纳入81项纵向糖尿病技术研究,共19148名非妊娠成人1型糖尿病患者,涉及70种不同的PROMs。
主要发现
- 与对照相比,技术使用与低血糖恐惧调查(HFS)总分降低相关(SMD -0.177;95%CI -0.319, -0.036;P=0.014;I2=0.0%),自动胰岛素装置使用者效应最大。
- 糖尿病技术对糖尿病治疗满意度问卷(DTSQs和DTSQc)评分有中等正向效应(SMD 0.429;95%CI 0.206, 0.653;P<0.001;I2=72.3%)。
- 糖尿病痛苦量表(DDS)和问题区域糖尿病(PAID)评分有轻至中度降低(SMD -0.265;95%CI -0.363, -0.166;P<0.001;I2=0.0%)。
关键数值与推荐
- HFS是最常用的PROM(k=39项研究),其次是DTSQs或DTSQc(k=38)、DDS(k=25)和PAID(k=24)。
临床怎么用
- 在成人1型糖尿病管理中,可考虑使用糖尿病技术以改善低血糖恐惧、治疗满意度和糖尿病痛苦等患者报告结局。
- 临床应关注PROMs的标准化使用,以便更一致地评估技术对患者体验的影响。
局限性
- 研究间技术类型存在差异。
- PROMs的使用方式多样且报告不完整。
- 研究持续时间不同。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Use of technology is central to the management of type 1 diabetes (T1D), while patient reported outcomes measures (PROMs) can support in the management of these individuals. PURPOSE: To assess the effect of diabetes technologies on patient-reported outcome measures (PROMs) in type 1 diabetes (T1D). DATA SOURCES: Cochrane Library CENTRAL, Embase, MEDLINE, Scopus, and Web of Science were searched for relevant articles from 2013 to August 2025. STUDY SELECTION: We included longitudinal diabetes technology studies assessing validated PROMs in nonpregnant adults with T1D. DATA EXTRACTION: Study characteristics and PROM data were extracted, and standardized mean differences (SMDs) for PROs were pooled using a random-effects meta-analysis. DATA SYNTHESIS: We identified 4,885 articles, comprising 81 independent studies (n = 19,148 participants) and 70 different PROMs. The Hypoglycemia Fear Survey (HFS) was most commonly used (k = 39 studies), followed by the Diabetes Treatment Satisfaction Questionnaire (status [DTSQs] or change version [DTSQc]; k = 38), Diabetes Distress Scale (DDS; k = 25), and Problem Areas in Diabetes (PAID) scale (k = 24). Technology use was associated with lower HFS total score compared with control (SMD -0.177; 95% CI -0.319, -0.036; P = 0.014; I2 = 0.0%), with the largest effect observed in automated insulin device users. A moderate positive effect of diabetes technologies was observed on DTSQs and DTSQc scores (SMD 0.429; 95% CI 0.206, 0.653; P < 0.001; I2 = 72.3%), with a small to moderate reduction in DDS and PAID scores (SMD -0.265; 95% CI -0.363, -0.166; P < 0.001; I2 = 0.0%). LIMITATIONS: Differences in type of technology, varied use and incomplete reporting of PROMs, and different duration of studies. CONCLUSIONS: Diabetes technologies offer psychological benefits in adults with T1D. The large number of reported PROMs suggests a need to standardize their use.
引用
- Gao M, Saravanan S, Munyombwe T, et al. Effects of Modern Glucose Monitoring and Insulin Delivery Technologies on Patient-Reported Outcomes and Experiences in Individuals With Type 1 Diabetes: A Systematic Review and Meta-analysis. Diabetes Care. 2025. PMID: 41166569. doi:10.2337/dc25-1178
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。